Primiano Christopher Brett 4
4 · Karyopharm Therapeutics Inc. · Filed Dec 3, 2020
Insider Transaction Report
Form 4
Primiano Christopher Brett
VP, Gen Counsel & Secretary
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2020-12-01−58,937→ 16,842 totalExercise: $10.39Exp: 2027-01-19→ Common Stock (58,937 underlying) - Sale
Common Stock
2020-12-01$17.66/sh−78,124$1,379,670→ 4,523 total - Exercise/Conversion
Common Stock
2020-12-01$10.39/sh+58,937$612,355→ 63,460 total - Sale
Common Stock
2020-12-01$17.35/sh−58,937$1,022,557→ 4,523 total - Exercise/Conversion
Common Stock
2020-12-01$10.45/sh+78,124$816,396→ 82,647 total - Exercise/Conversion
Stock Option (right to buy)
2020-12-01−78,124→ 46,876 totalExercise: $10.45Exp: 2028-01-23→ Common Stock (78,124 underlying)
Footnotes (3)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 24, 2019, with the remaining 75% vesting in 36 equal monthly installments thereafter.
- [F3]This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 20, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter.